Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells
The authors consider the potential application of therapeutic doses of irradiation, the well-known and effective stress signal that induces DNA damage and activates cellular stress response, to resolve two problems: activate HIV-1 replication and virion production in persistent reservoirs under cART and deplete infected cells via the selective cell killing using DNA damage responses. [AIDS Res Hum Retroviruses] Abstract
Visit our reviews page to see a complete list of reviews in the Immunology of Infectious Disease research field.
Dengue Vaccine Enters Phase III Trial in Brazil
A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH’s National Institute of Allergy and Infectious Diseases. [National Institutes of Health] Press Release
Profectus BioSciences Initiates Ebola Vaccine Phase I Clinical Trial
Profectus BioSciences, Inc. announced the initiation of a Phase I clinical study of Profectus’ VesiculoVax™-vectored Ebola virus vaccine. The vaccine is a version of the company’s patented VSV vector that has been engineered for safe use in humans and to express the surface protein of Ebola virus. [Profectus BioSciences, Inc.] Press Release
Telephus Medical LLC Announces Issuance of Japanese Patent for Anti-MRSA Antibodies
Telephus Medical LLC announced that the Japan Patent Office has issued Japanese patent number 5,837,215 covering monoclonal antibody compositions that bind and neutralize the endo-β-N-acetylglucosaminidase subunit of staphylococcal bifunctional autolysin and methods to use those antibodies for the treatment and prevention of severe, life-threatening staph infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). [Telephus Medical LLC (Business WIre)] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Immunology of Infectious Disease News? Click here to submit!